Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76. https://doi.org/10.1093/jnci/85.5.365.

Article  CAS  PubMed  Google Scholar 

Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14:2756–68. https://doi.org/10.1200/JCO.1996.14.10.2756.

Article  CAS  PubMed  Google Scholar 

Musoro JZ, Coens C, Fiteni F, Katarzyna P, Cardoso F, Russell NS, et al. Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer. JNCI Cancer Spectr. 2019;3(3):pkz037. https://doi.org/10.1093/jncics/pkz037.

Article  PubMed  PubMed Central  Google Scholar 

Musoro JZ, Coens C, Sprangers MAG, Brandberg Y, Groenvold M, Flechtner H, et al. Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: a synthesis across 21 clinical trials involving nine different cancer types. Eur J Cancer. 2023;188:171–82. https://doi.org/10.1016/j.ejca.2023.04.027.

Article  PubMed  Google Scholar 

Goetz MP, Martin M, Tokunaga E, Park IH, Huober J, Toi M, et al. Health-related quality of life in MONARCH 3: abemaciclib plus an aromatase inhibitor as initial therapy in HR+, HER2 − advanced breast cancer. Oncologist. 2020;25(9):e1346–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harbeck N, Iyer S, Turner N, Cristofanilli M, Ro J, André F, et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol. 2016;27:1047–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Curigliano G, Dunton K, Rosenlund M, Janek M, Cathcart J, Liu Y, et al. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study. Ann Oncol. 2023;34(7):569–77. https://doi.org/10.1016/j.annonc.2023.04.516.

Article  CAS  PubMed  Google Scholar 

Adams S, Diéras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, et al. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol. 2020;31(5):582–9. https://doi.org/10.1016/j.annonc.2020.02.003.

Article  CAS  PubMed  Google Scholar 

Kawahara T, Taira N, Shiroiwa T, Hagiwara Y, Fukuda T, Uemura Y, et al. Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: results from a randomized clinical trial. Qual Life Res. 2022;31(6):1829–36. https://doi.org/10.1007/s11136-021-03074-y.

Article  PubMed  PubMed Central  Google Scholar 

Takahashi M, Kikawa Y, Kashiwabara K, Taira N, Iwatani T, Shimozuma K, et al. Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial. EClinicalMedicine. 2024;74:102715.

Article  PubMed  PubMed Central  Google Scholar 

Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.

Google Scholar 

Oken MM, Creech RH, Davis TE. Toxicology and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.

Article  CAS  Google Scholar 

Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102–9.

Article  PubMed  Google Scholar 

Cohen J. Statistical power analysis for the behavioral sciences. Milton Park: Routledge; 1988. https://doi.org/10.4324/9780203771587.

Book  Google Scholar 

Mukai H, Uemura Y, Akabane H, Watanabe T, Park Y, Takahashi M, et al. Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer. Br J Cancer. 2021;125(9):1217–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide plus filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol. 2003;21(5):843–50.

Article  CAS  PubMed  Google Scholar 

Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol. 2002;20(14):3114–21.

Article  CAS  PubMed  Google Scholar 

Kikawa Y, Uemura Y, Taira T, Kitagawa C, Maeda H, Kato H et al. A randomized study comparing electronic patient-reported outcomes monitoring with routine follow-up during trastuzumab deruxtecan treatment for inoperable or metastatic breast cancer patients: PRO-DUCE study. ASCO Annual Meeting. (2024)